X
    X
    X
    X

    Juvenescence Limited

    A Locke Lord team led by Eugene McDermott, Douglas Gray and Baker Coon (all of Providence), represented Juvenescence Limited, a leading drug development company based in the British Virgin Islands, focused on the development of therapies to increase human longevity, in its purchase of 14.4 million shares of AgeX Therapeutics, Inc. for $43.2 million, from its affiliate BioTime, Inc. (NYSE American: BTX). AgeX is focused on developing novel therapeutics for age-related degenerative disease. Additional team members included Karl Fryzel, Ralph Loren (both of Boston), Jason Ulezalka (New York), Stephen Murphy (Washington, D.C.) and Michael Conroy (Chicago).
    Posted on November 1, 2018

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.